Affymax Reveals Receipt Of $30 Mln Milestone Payment From Takeda- Update - Stock Markets Review Print
Stock Markets ReviewIt had two studies in dialysis patients dubbed EMERALD 1and EMERALD 2, and two other studies dubbed PEARL 1 and PEARL 2 in non-dialysis patients.

... read more